284. Diamond-Blackfan anemia Clinical trials / Disease details

Clinical trials : 36 / Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-000766-20-GB (EUCTR)	17/07/2008	13/12/2007	A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA	A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA	Beta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as indicated by a T2* =6 but not greater than 20 ms, with no symptoms of cardiac dysfunction, and an MRI measured LVEF =56%.	Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Desferal Product Name: Desferal Product Code: DFO INN or Proposed INN: deferoxamine Trade Name: Desferal Product Name: Desferal Product Code: DFO	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	192	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Italy;United Kingdom